Intratumoral modeling of gefitinib pharmacokinetics and pharmacodynamics in an orthotopic mouse model of glioblastoma

Cancer Research

Volumn 73, Issue 16, 2013, Pages 5242-5252

  Sharma, Jyoti ^a,b   Lv, Hua ^b   Gallo, James M ^b  

^a TEMPLE UNIVERSITY   (United States)

^b MOUNT SINAI SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

GEFITINIB; MITOGEN ACTIVATED PROTEIN KINASE;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; AREA UNDER THE CURVE; ARTICLE; BLOOD BRAIN BARRIER; CONTROLLED STUDY; DRUG ABSORPTION; DRUG BIOAVAILABILITY; DRUG DISTRIBUTION; DRUG DOSE COMPARISON; DRUG MEGADOSE; DRUG PENETRATION; DRUG TUMOR LEVEL; GLIOBLASTOMA; IMMUNOHISTOCHEMISTRY; LOW DRUG DOSE; MALE; MATHEMATICAL MODEL; MOUSE; NONHUMAN; PHARMACODYNAMICS; PRIORITY JOURNAL; PROTEIN PHOSPHORYLATION;

EID: 84882677186     PISSN: 00085472     EISSN: 15387445     Source Type: Journal    
DOI: 10.1158/0008-5472.CAN-13-0690     Document Type: Article

References (50)

1. Iacob G, Dinca EB. Current data and strategy in glioblastoma multiforme. J Med Life 2009;2:386-93.
2. Louis DN, Ohgaki H, Wiestler OD, Cavenee WK, Burger PC, Jouvet A , et al. The 2007 WHO classification of tumours of the central nervous system. Acta Neuropathol 2007;114:97-109.
3. Jung V, Romeike BF, Henn W, FeidenW, Moringlane JR, Zang KD, et al. Evidence of focal genetic microheterogeneity in glioblastoma multiforme by area-specific CGH on microdissected tumor cells. J Neuropathol Exp Neurol 1999;58:993-9.
4. Bonavia R, Inda MM, Cavenee WK, Furnari FB. Heterogeneity maintenance in glioblastoma: a social network. Cancer Res 2011;71: 4055-60.
5. Little SE, Popov S, Jury A, Bax DA, Doey L, Al-Sarraj S, et al. Receptor tyrosine kinase genes amplified in glioblastoma exhibit a mutual exclusivity in variable proportions reflective of individual tumor heterogeneity. Cancer Res 2012;72: 1614-20.
6. Jain RK, di Tomaso E, Duda DG, Loeffler JS, Sorensen AG, Batchelor TT. Angiogenesis in brain tumours. Nat Rev Neurosci 2007;8: 610-22.
7. Schlageter KE, Molnar P, Lapin GD, Groothuis DR. Microvessel organization and structure in experimental brain tumors: microvessel populations with distinctive structural and functional properties. Microvasc Res 1999;58:312-28.
8. Weissleder R, Cheng HC, Marecos E, Kwong K, Bogdanov A Jr. Noninvasive in vivo mapping of tumour vascular and interstitial volume fractions. Eur J Cancer 1998;34:1448-54.
9. Jain R, Gutierrez J, Narang J, Scarpace L, Schultz LR, Lemke N, et al. In vivo correlation of tumor blood volume and permeability with histologic and molecular angiogenic markers in gliomas. AJNR Am J Neuroradiol 2011;32:388-94.
10. Vavra M, Ali MJ, Kang EW, Navalitloha Y, Ebert A, Allen CV, et al. Comparative pharmacokinetics of 14C-sucrose in RG-2 rat gliomas after intravenous and convection-enhanced delivery. Neuro Oncol 2004;6:104-12.
11. Paulus W, Peiffer J. Intratumoral histologic heterogeneity of gliomas. A quantitative study. Cancer 1989;64:442-7.
12. Coons SW, Johnson PC. Regional heterogeneity in the proliferative activity of human gliomas as measured by the ki-67 labeling index. J Neuropathol Exp Neurol 1993;52:609-18.
13. Cheng LL, Anthony DC, Comite AR, Black PM, Tzika AA, Gonzalez RG. Quantification of microheterogeneity in glioblastoma multiforme with ex vivo high-resolution magic-angle spinning (HRMAS) proton magnetic resonance spectroscopy. Neuro Oncol 2000;2: 87-95.
14. Wagner M, Nafe R, Jurcoane A, Pilatus U, Franz K, Rieger J, et al. Heterogeneity in malignant gliomas: a magnetic resonance analysis of spatial distribution of metabolite changes and regional blood volume. J Neurooncol 2011;103:663-72.
15. Horowitz M, Blasberg R, Molnar P, Strong J, Kornblith P, Pleasants R, et al. Regional [14C]misonidazole distribution in experimental RT-9 brain tumors. Cancer Res 1983;43:3800-7.
16. Lockman PR, Mittapalli RK, Taskar KS, Rudraraju V, Gril B, Bohn KA, et al. Heterogeneous blood-tumor barrier permeability determines drug efficacy in experimental brain metastases of breast cancer. Clin Cancer Res 2010;16:5664-78.
17. Reyzer ML, Hsieh Y, Ng K, Korfmacher WA, Caprioli RM. Direct analysis of drug candidates in tissue by matrix-assisted laser desorption/ ionization mass spectrometry. J Mass Spectrom 2003;38: 1081-92.
18. Gelderblom H, Verweij J, van Zomeren DM, Buijs D, Ouwens L, Nooter K, et al. Influence of cremophor el on the bioavailability of intraperitoneal paclitaxel. Clin Cancer Res 2002;8:1237-41.
19. Agarwal S, Mittapalli RK, Zellmer DM, Gallardo JL, Donelson R, Seiler C, et al. Active efflux of dasatinib from the brain limits efficacy against murine glioblastoma: broad implications for the clinical use of molecularly- targeted agents. Mol Cancer Ther 2012;11:2183-92.
20. Donelli MG, Zucchetti M, D'Incalci M. Do anticancer agents reach the tumor target in the human brain? Cancer Chemother Pharmacol 1992;30:251-60.
21. Pitz MW, Desai A, Grossman SA, Blakeley JO. Tissue concentration of systemically administered antineoplastic agents in human brain tumors. J Neurooncol 2011;104:629-38.
22. Holdhoff M, Supko JG, Gallia GL, Hann CL, Bonekamp D, Ye X, et al. Intratumoral concentrations of imatinib after oral administration in patients with glioblastoma multiforme. J Neurooncol 2010;97:241-5.
23. Hofer S, Frei K. Gefitinib concentrations in human glioblastoma tissue. J Neurooncol 2007;82:175-6.
24. Zhou Q, Gallo JM. Differential effect of sunitinib on the distribution of temozolomide in an orthotopic glioma model. Neuro Oncol 2009; 11:301-10.
25. Sharma J, Lv H, Gallo JM. Analytical approach to characterize the intratumoral pharmacokinetics and pharmacodynamics of gefitinib in a glioblastoma model. J Pharm Sci 2012;101:4100-6.
26. Wang S, Guo P, Wang X, Zhou Q, Gallo JM. Preclinical pharmacokinetic/ pharmacodynamic models of gefitinib and the design of equivalent dosing regimens in EGFR wild-type and mutant tumor models. Mol Cancer Ther 2008;7:407-17.
27. Sun Y, Schmidt NO, Schmidt K, Doshi S, Rubin JB, Mulkern RV, et al. Perfusion MRI of U87 brain tumors in a mouse model. Magn Reson Med 2004;51:893-9.
28. Pathak AP, Kim E, Zhang J, Jones MV. Three-dimensional imaging of the mouse neurovasculature with magnetic resonance microscopy. PLoS ONE 2011;6:e22643.
29. Gambarota G, Leenders W, Maass C, Wesseling P, van der Kogel B, van Tellingen O, et al. Characterisation of tumour vasculature in mouse brain by USPIO contrast-enhanced MRI. Br J Cancer 2008;98:1784-9.
30. Ozvegy-Laczka C, Hegedus T, Varady G, Ujhelly O, Schuetz JD, Varadi A, et al. High-affinity interaction of tyrosine kinase inhibitors with the ABCG2 multidrug transporter. Mol Pharmacol 2004;65:1485-95.
31. Jain RK. Delivery of molecular and cellular medicine to solid tumors. Adv Drug Deliv Rev 2001;46:149-68.
32. Agarwal S, Sane R, Gallardo JL, Ohlfest JR, Elmquist WF. Distribution of gefitinib to the brain is limited by P-glycoprotein (ABCB1) and breast cancer resistance protein (ABCG2)-mediated active efflux. J Pharmacol Exp Ther 2010;334:147-55.
33. Sawada T, Kato Y, Sakayori N, Takekawa Y, Kobayashi M. Expression of the multidrug-resistance P-glycoprotein (pgp, MDR-1) by endothelial cells of the neovasculature in central nervous system tumors. Brain Tumor Pathol 1999;16:23-7.
34. Sharma A, Jusko WJ. Characteristics of indirect pharmacodynamic models and applications to clinical drug responses. Br J Clin Pharmacol 1998;45:229-39.
35. Fellner S, Bauer B, Miller DS, Schaffrik M, Fankhanel M, Spruss T, et al. Transport of paclitaxel (taxol) across the blood-brain barrier in vitro and in vivo. J Clin Invest 2002;110:1309-18.
36. Nishikawa R, Ji XD, Harmon RC, Lazar CS, Gill GN, Cavenee WK, et al. A mutant epidermal growth factor receptor common in human glioma confers enhanced tumorigenicity. Proc Natl Acad Sci U S A 1994; 91:7727-31.
37. Morikawa S, Baluk P, Kaidoh T, Haskell A, Jain RK, McDonald DM. Abnormalities in pericytes on blood vessels and endothelial sprouts in tumors. Am J Pathol 2002;160:985-1000.
38. Daneman R, Zhou L, Kebede AA, Barres BA. Pericytes are required for blood-brain barrier integrity during embryogenesis. Nature 2010;468: 562-6.
39. Raza A, Franklin MJ, Dudek AZ. Pericytes and vessel maturation during tumor angiogenesis and metastasis. Am J Hematol 2010;85:593-8.
40. Goel S, Duda DG, Xu L, Munn LL, Boucher Y, Fukumura D, et al. Normalization of the vasculature for treatment of cancer and other diseases. Physiol Rev 2011;91:1071-121.
41. Rustum YM, Toth K, Seshadri M, Sen A, Durrani FA, Stott E, et al. Architectural heterogeneity in tumors caused by differentiation alters intratumoral drug distribution and affects therapeutic synergy of antiangiogenic organoselenium compound. J Oncol 2010;2010:396286.
42. Tailor TD, Hanna G, Yarmolenko PS, Dreher MR, Betof AS, Nixon AB, et al. Effect of pazopanib on tumor microenvironment and liposome delivery. Mol Cancer Ther 2010;9:1798-808.
43. McKillop D, Hutchison M, Partridge EA, Bushby N, Cooper CM, Clarkson-Jones JA, et al. Metabolic disposition of gefitinib, an epidermal growth factor receptor tyrosine kinase inhibitor, in rat, dog, and man. Xenobiotica 2004;34:917-34.
44. Fukuhara T, Saijo Y, Sakakibara T, Inoue A, Morikawa N, Kanamori M, et al. Successful treatment of carcinomatous meningitis with gefitinib in a patient with lung adenocarcinoma harboring a mutated EGF receptor gene. Tohoku J Exp Med 2008;214:359-63.
45. Hashizume H, Baluk P, Morikawa S, McLean JW, Thurston G, Roberge S, et al. Openings between defective endothelial cells explain tumor vessel leakiness. Am J Pathol 2000;156:1363-80.
46. Bergeron L, Bevan DR, Berrill A, Kahwaji R, Varin F. Concentrationeffect relationship of cisatracurium at three different dose levels in the anesthetized patient. Anesthesiology 2001;95:314-23.
47. Derendorf H, Meibohm B. Modeling of pharmacokinetic/pharmacodynamic (PK/PD) relationships: concepts and perspectives. Pharm Res 1999;16:176-85.
48. Lundstrom J, Lindgren JE, Ahlenius S, Hillegaart V. Relationship between brain levels of 3-(3-hydroxyphenyl)-N-n-propylpiperidine HCl enantiomers and effects on locomotor activity in rats. J Pharmacol Exp Ther 1992;262:41-7.
49. Brehmer D, Greff Z, Godl K, Blencke S, Kurtenbach A, Weber M, et al. Cellular targets of gefitinib. Cancer Res 2005;65:379-82.
50. Zhang L, Gjoerup O, Roberts TM. The serine/threonine kinase cyclin Gassociated kinase regulates epidermal growth factor receptor signaling. Proc Natl Acad Sci U S A 2004;101:10296-301.